Use of sevelamer hydrochloride and calcium carbonate in the control of hyperphosphatemia in patients in hemodialysis
To evaluate the effectiveness of sevelamer and calcium carbonate as phosphate binder. METHODS: We selected 31 patients (55±14 years) who underwent haemodyalisis (HD) 3 times / week 4 h / session, which were raised test results in zero time and end time, split into 3 groups: GI: in use of calcium car...
| Autores: | , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2009 |
| País: | Brasil |
| Institución: | Universidade Nove de Julho (UNINOVE) |
| Repositorio: | Revista Conscientiae Saúde (Online) |
| Idioma: | portugués |
| OAI Identifier: | oai:ojs.periodicos.uninove.br:article/1734 |
| Acceso en línea: | https://periodicos.uninove.br/saude/article/view/1734 |
| Access Level: | acceso abierto |
| Palabra clave: | Carbonato de cálcio Doença renal crônica classe V Hiperparatireoidismo secundário Sevelamer. |
| Sumario: | To evaluate the effectiveness of sevelamer and calcium carbonate as phosphate binder. METHODS: We selected 31 patients (55±14 years) who underwent haemodyalisis (HD) 3 times / week 4 h / session, which were raised test results in zero time and end time, split into 3 groups: GI: in use of calcium carbonate; GII: in use of sevelamer; GIII: without the use of phosphate binders. The GII showed a trend for higher number of extra sessions of dialysis and longer HD versus GI. The level of calcium tended to be different in GII vs GI. There was a trend for higher initial level of phosphorus GII vs GIII. Sevelamer has great therapeutic value and is of paramount importance to CKD V patients on dialysis hypercalcemic. There is evidence that in the long term, the use of sevelamer bring benefits in reducing the morbidity associated with haemodialysis. |
|---|